权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MicroRNA regulation of CD38 and chemokine genes in human airway smooth muscle

MicroRNA对人气道平滑肌CD38和趋化因子基因的调控

基本信息

批准号：
9242566
负责人：
MATHUR S KANNAN
金额：
$ 19.08万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-03-15 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9242566
关键词：
1-Phosphatidylinositol 3-Kinase 3&apos Untranslated Regions Address Adenosine Adenosine A2B Receptor Adenosine Diphosphate Ribose Adverse effects Affinity Allergens Allergic inflammation Alpha Cell Animal Model Asthma Binding Bone Marrow Bronchial Spasm Bronchoalveolar Lavage Bronchoconstriction Bypass Calcium Calcium Signaling Cause of Death Cell Surface Proteins Cell surface Cells Chronic Chronic Obstructive Airway Disease Chronic lung disease Clinical Trials Cyclic ADP-Ribose Disease Enzymes G-Protein-Coupled Receptors G-substrate GTP-Binding Proteins Generations Genes Genetic Growth Factor Health Care Costs Human Hydrolase IL5 gene Inflammation Inflammatory Interleukin-13 Interleukin-4 Interleukin-6 Intracellular Transport Laboratories Lead Lung Lung Inflammation Mediating Mediator of activation protein Metabolism MicroRNAs Mitogen-Activated Protein Kinase Kinases Molecular Mus Muscle Cells NAADP Natural Immunity Nucleoside Transporter Pathogenesis Pathway interactions Periodicity Pharmaceutical Preparations Phenotype Play Production Protein Dephosphorylation Proteins Pulmonary Pathology Purinergic P1 Receptors Pyroglyphidae Regulation Role Signal Transduction Site Small Interfering RNA Source Stimulus Structure of parenchyma of lung Testing Therapeutic Intervention Tissues airway hyperresponsiveness airway inflammation airway remodeling arm asthmatic asthmatic airway attenuation chemokine cytokine enzyme activity extracellular in vivo inflammatory milieu knock-down mouse model novel plasma cell membrane glycoprotein PC-1 public health relevance receptor receptor density respiratory smooth muscle response therapeutic target

项目摘要

DESCRIPTION (provided by applicant): Chronic lung diseases such as asthma and COPD are one of the leading causes of death in the US and the mechanisms for the progressive remodeling of lung tissue that occurs in these diseases are incompletely understood. Adenosine levels are elevated in the lungs of these subjects where it engages four subtypes of receptors which results in the release of the pro-fibrotic cytokine IL-6, leading to augmented bronchoconstriction to stimuli, airway inflammation and remodeling. In animal models, decreasing the accumulation of adenosine is known to alter the course of lung inflammation and increase survival. The bronchospastic response in subjects with asthma and COPD to adenosine is not seen in normal subjects, indicating that the underlying mechanisms of increased bronchospasm, airway inflammation and remodeling are augmented in these diseases. Adenosine is generated by dephosphorylation of ATP at sites of inflammation and remodeling as well as generated intracellularly and transported through the nucleoside transporters. In this proposal, we will generate evidence that CD38, a cell surface protein expressed in airway smooth muscle, is a significant source of adenosine from NAD+ by the enzymatic cascade CD38/CD203a/CD73. The enzymatic activity that converts NAD+ to AMP involves CD38 whose expression in airway smooth muscle is augmented by inflammatory and Th2 cytokines and to a greater extent in cells derived from asthmatics. This pathway of adenosine and IL-6 production are sufficient to cause airway hyperresponsiveness, airway inflammation and airway remodeling independent of the roles of CD38 in intracellular calcium signaling and innate immunity. Thus we postulate that inhibiting CD38 expression in airway smooth muscle will limit the progression of chronic lung diseases by decreasing adenosine and IL-6. In the studies with airway smooth muscle cells from asthmatics and non-asthmatics maintained in an inflammatory environment, in a mouse model of chronic allergen challenge and in the Cd38-/- mice, we will provide evidence for airway smooth muscle as a significant source of adenosine and IL-6 and that targeting the enzymes involved in the conversion of NAD+ to adenosine can reverse the lung damage. We have identified the roles of two specific miRNAs in the regulation of CD38 expression and will demonstrate their ability to decrease adenosine and IL-6 release in airway smooth muscle cells and reversal of the airway phenotype by delivering in vivo in mice.

描述（由申请人提供）：慢性肺部疾病（如哮喘和COPD）是美国的主要死因之一，并且对这些疾病中发生的肺组织进行性重塑的机制尚未完全了解。腺苷水平在这些受试者的肺中升高，其中腺苷与四种受体亚型结合，导致促纤维化细胞因子IL-6的释放，导致对刺激的支气管收缩增强、气道炎症和重塑。在动物模型中，已知减少腺苷的积累可以改变肺部炎症的过程并增加存活率。哮喘和COPD受试者对腺苷的支气管痉挛反应在正常受试者中未见，表明支气管痉挛增加、气道炎症和重塑的潜在机制在这些疾病中增强。腺苷是通过ATP在炎症和重塑部位的去磷酸化产生的，也可以在细胞内产生并通过核苷转运蛋白转运。在这个建议中，我们将产生的证据表明，CD 38，在气道平滑肌中表达的细胞表面蛋白，是一个重要的来源，腺苷从NAD+的酶级联CD 38/CD 203 a/CD 73。将NAD+转化为AMP的酶活性涉及CD 38，其在气道平滑肌中的表达被炎性和Th 2细胞因子增强，并且在更大程度上在源自哮喘患者的细胞中增强。这种腺苷和IL-6产生的途径足以引起气道高反应性、气道炎症和气道重塑，而不依赖于CD 38在细胞内钙信号传导和先天免疫中的作用。因此，我们推测，抑制气道平滑肌中的CD 38表达将通过减少腺苷和IL-6来限制慢性肺病的进展。在研究中，来自哮喘患者和非哮喘患者的气道平滑肌细胞保持在炎症环境中，在慢性过敏原激发的小鼠模型和Cd 38-/-小鼠中，我们将提供气道平滑肌作为腺苷和IL-6的重要来源的证据，并且靶向参与NAD+转化为腺苷的酶可以逆转肺损伤。我们已经确定了两种特异性miRNA在调节CD 38表达中的作用，并将通过在小鼠体内递送来证明它们减少气道平滑肌细胞中腺苷和IL-6释放以及逆转气道表型的能力。